Evidence-based prescribing of drugs for secondary prevention of acute coronary syndrome in Aboriginal and non-Aboriginal patients admitted to Western Australian hospitals

Internal Medicine Journal

Volumn 44, Issue 4, 2014, Pages 353-361

  Gausia, K ^a   Katzenellenbogen, J M ^a   Sanfilippo, F M ^b   Knuiman, M W ^b   Thompson, P L ^c   Hobbs, M S T ^b   Thompson, S C ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Aboriginal; Acute coronary syndrome; Discharge prescription; Evidence based prescribing; Hospital; Secondary preventive drugs; Western Australia

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ASTHMA; AUSTRALIA; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; EVIDENCE BASED PRACTICE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HYPERTENSION; INDIGENOUS PEOPLE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MONOTHERAPY; OUTCOME ASSESSMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PRIVATE HOSPITAL; PUBLIC HOSPITAL; RANDOM SAMPLE; SECONDARY PREVENTION; SMOKING; TEACHING HOSPITAL; UNSTABLE ANGINA PECTORIS; CLINICAL TRIAL; COMPARATIVE STUDY; EPIDEMIOLOGY; ETHNOLOGY; EVIDENCE BASED MEDICINE; FOLLOW UP; MIDDLE AGED; MORBIDITY; MULTICENTER STUDY; OCEANIC ANCESTRY GROUP; PRACTICE GUIDELINE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; STANDARDS; TRENDS;

ACUTE CORONARY SYNDROME; AGED; DRUG PRESCRIPTIONS; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; MORBIDITY; OCEANIC ANCESTRY GROUP; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; WESTERN AUSTRALIA;

EID: 84899046944     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12375     Document Type: Article

References (35)

1. Australian Institute of Health and Welfare. Monitoring Acute Coronary Syndrome using National Hospital Data: An Information Paper on Trends and Issues. Canberra: AIHW; 2011.
2. Deloitte Access Economics. ACS in perspective: the importance of secondary prevention, 2011.
3. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R etal. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; 378: 1231-1243.
4. Brown A. Acute coronary syndromes in indigenous Australians: opportunities for improving outcomes across the continuum of care. Heart Lung Circ 2010; 19: 325-336.
5. Katzenellenbogen JM, Sanfilippo FM, Hobbs MST, Briffa TG, Ridout SC, Knuiman MW etal. Incidence of and case fatality following acute myocardial infarction in Aboriginal and Non-Aboriginal Western Australians (2000-2004): a linked data study. Heart Lung Circ 2010; 19: 717-725.
6. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109: 1101-1107.
7. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010; 121: 750-758.
8. Peterson ED, Shah BR, Parsons L, Pollack CV Jr, French WJ, Canto JG etal. Trends in quality of care for patients with acute myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156: 1045-1055.
9. Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ etal. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
10. National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Guidelines for the management of acute coronary syndromes. Med J Aust 2006; 184(8 Suppl): S9-29.
11. Chew DP, Aroney CN, Aylward PE, Kelly AM, White HD, Tideman PA etal. Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung Circ 2011; 20: 487-502.
12. Wai A, Pulver LK, Oliver K, Thompson A. Current discharge management of acute coronary syndromes: baseline results from a national quality improvement initiative. Intern Med J 2012; 42: e53-59.
13. Vermeer NS, Bajorek BV. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. J Clin Pharm Ther 2008; 33: 591-601.
14. Chew DP, Amerena J, Coverdale S, Rankin J, Astley C, Brieger D. Current management of acute coronary syndromes in Australia: observations from the acute coronary syndromes prospective audit. Intern Med J 2007; 37: 741-748.
15. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O etal. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-1189.
16. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
17. van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A. Effect of drug combinations on admission for recurrent myocardial infarction. Heart 2007; 93: 1226-1230.
18. Mukherjee D, Fang J, Chetcuti S, Moscucci M, Kline-Rogers E, Eagle KA. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745-749.
19. van der Elst ME, Buurma H, Bouvy ML, de Boer A. Drug therapy for prevention of recurrent myocardial infarction. Ann Pharmacother 2003; 37: 1465-1477.
20. Holman CDAJ, Bass AJ, Rouse IL, Hobbs MST. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999; 23: 453-459.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
22. Al-Zakwani I, Zubaid M, Panduranga P, Rashed W, Sulaiman K, Almahmeed W etal. Medication use pattern and predictors of optimal therapy at discharge in 8176 patients with acute coronary syndrome from 6 Middle Eastern countries: data from the gulf registry of acute coronary events. Angiology 2011; 62: 447-454.
23. Bi Y, Gao R, Patel A, Su S, Gao W, Hu D etal. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J 2009; 157: 509-516. e1.
24. Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E etal. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 2010; 96: 604-609.
25. Lee JH, Yang DH, Park HS, Cho Y, Jeong MH, Kim YJ etal. Suboptimal use of evidence-based medical therapy in patients with acute myocardial infarction from the Korea Acute Myocardial Infarction Registry: prescription rate, predictors, and prognostic value. Am Heart J 2010; 159: 1012-1019.
26. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ etal. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007; 154: 1108-1115.
27. Navas EV, Taylor DO. Can patients with COPD or asthma take a beta-blocker? Cleve Clin J Med 2010; 77: 498-499.
28. Salpeter SR, Ormiston TM, Salpeter EE, Poole PJ, Cates CJ. Cardioselective beta-blockers for chronic obstructive pulmonary disease: a meta-analysis. Respir Med 2003; 97: 1094-1101.
29. Scott IA. Discordance between level of risk and intensity of evidence-based treatment in patients with acute coronary syndromes. Med J Aust 2007; 187: 479.
30. Joynt KE, Huynh L, Amerena JV, Brieger DB, Coverdale SG, Rankin JM etal. Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes. Heart 2009; 95: 1442-1448.
31. Funkhouser E, Houston TK, Levine DA, Richman J, Allison JJ, Kiefe CI. Physician and patient influences on provider performance: beta-blockers in postmyocardial infarction management in the MI-Plus study. Circ Cardiovasc Qual Outcomes 2011; 4: 99-106.
32. Chew DP, French J, Briffa TG, Hammett CJ, Ellis CJ, Ranasinghe I etal. Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. Med J Aust 2013; 199: 185-191.
33. Rutten FH, Grobbee DE, Hoes AW. Differences between general practitioners and cardiologists in diagnosis and management of heart failure: a survey in every-day practice. Eur J Heart Fail 2003; 5: 337-344.
34. Vassilikos VP, Mantziari A, Goudis CA, Paraskevaidis S, Dakos G, Giannakoulas G etal. Differences in management of atrial fibrillation between cardiologists and non-cardiologists in Greece. Hellenic J Cardiol 2010; 51: 113-121.
35. Peterson GM, Thompson A, Pulver LK, Robertson MB, Brieger D, Wai A etal. Management of acute coronary syndromes at hospital discharge: do targeted educational interventions improve practice quality? J Healthc Qual 2012; 34: 26-34.